Chemotherapy suppresses SHH gene expression via a specific enhancer

J Genet Genomics. 2023 Jan;50(1):27-37. doi: 10.1016/j.jgg.2022.08.002. Epub 2022 Aug 20.

Abstract

Sonic hedgehog (SHH) signaling is a key regulator of embryonic development and tissue homeostasis that is involved in gastrointestinal (GI) cancer progression. Regulation of SHH gene expression is a paradigm of long-range enhancer function. Using the classical chemotherapy drug 5-fluorouracil (5FU) as an example, here we show that SHH gene expression is suppressed by chemotherapy. SHH is downstream of immediate early genes (IEGs), including Early growth response 1 (Egr1). A specific 139 kb upstream enhancer is responsible for its down-regulation. Knocking down EGR1 expression or blocking its binding to this enhancer renders SHH unresponsive to chemotherapy. We further demonstrate that down-regulation of SHH expression does not depend on 5FU's impact on nucleotide metabolism or DNA damage; rather, a sustained oxidative stress response mediates this rapid suppression. This enhancer is present in a wide range of tumors and normal tissues, thus providing a target for cancer chemotherapy and its adverse effects on normal tissues. We propose that SHH is a stress-responsive gene downstream of IEGs, and that traditional chemotherapy targets a specific enhancer to suppress its expression.

Keywords: 5-Fluorouracil; Chemotherapy; EGR1; Immediate early genes; Sonic hedgehog.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Down-Regulation
  • Enhancer Elements, Genetic* / genetics
  • Fluorouracil / pharmacology
  • Gene Expression
  • Gene Expression Regulation, Developmental
  • Hedgehog Proteins* / genetics
  • Hedgehog Proteins* / metabolism

Substances

  • Hedgehog Proteins
  • Fluorouracil